Grifols S.A. ADR (GRFS)

$6.36 0.19 (2.83%)

14:03 EDT GRFS Stock Quote Delayed 30 Minutes

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Mar 8, 2024

We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!

10 Things to Know as Gotham City Slams Grifols (GRFS) Stock in New Short Report

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

7 Pharmaceutical Stocks to Buy for Post-Pandemic Gains

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 560,305

Day's Range $6.33 - $6.46

52-Week Range $5.30 - $12.15

Dividend & Yield N/A (N/A)

GRFS Stock Predictions, Articles, and Grifols S.A. ADR News

From InvestorPlace
From the Web

2 Stable and 2 Speculative Biotech Stocks to Buy

By Josh Enomoto, InvestorPlace Contributor Jun 15, 2018

Biotech stocks are incredibly wild affairs, but if you have an iron stomach, these four companies could potentially offer serious upside.

Biggest Movers in Manufacturing Stocks Now – BOSC TCON VTVT GRFS

By Portfolio Grader Dec 15, 2016

The following stocks were moving the Manufacturing sector today.

13 Biotechnology Stocks to Sell Now

By Portfolio Grader Oct 3, 2016

The overall ratings of 13 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

23 Biotechnology Stocks to Sell Now

By Portfolio Grader Sep 26, 2016

This week, the overall grades of 23 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

11 Biotechnology Stocks to Buy Now

By Portfolio Grader Jun 6, 2016

The grades of 11 Biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").

40 Upgrades and Downgrades for this Week

By Jun 1, 2016

It pays to stay on top of the latest profit opportunities, and today's post is a great place to start. Here are Portfolio Grader's latest stock updates

73 Stock Trades for Your Week

By Mar 8, 2016

During these times it pays to stay on top of the latest profit opportunities. Today's blog post should be a great place to start with these 73 stock trades

Investor Alert: Know Before You Buy These 57 Blue Chips

By Mar 1, 2016

It pays to stay on top of the latest profit opportunities. Today's blog post is a great place to start with the latest Portfolio Grader marks

64 Actions to Take on Monday’s Market Dip

By Feb 9, 2016

It pays to stay on top of the latest profit opportunities, and today's blog post is a great place to start after Monday's route

7 Healthcare Stocks to Kick to the Curb

By Louis Navellier, Editor, Growth Investor Jun 26, 2015

Not all stocks in the healthcare sector have bright prospects moving forward. These seven healthcare stocks are dogs that are best to be avoided, for now.

Activist investors boosting stakes in short seller targets Temenos, Grifols

From Seeking Alpha Feb 21, 2024

Activist investors are increasing their holdings in Temenos AG and Grifols, despite recent short seller reports.

Grifols stock gains on new CEO appointment (NASDAQ:GRFS)

From Seeking Alpha Feb 5, 2024

Grifols (GRFS) announces new CEO and other leadership changes as founding family members step down. Read more here.

Grifols banking exposure under ECB scrutiny (NASDAQ:GRFS)

From Seeking Alpha Jan 17, 2024

The European Central Bank has contacted lenders to Grifols (GRFS) regarding their exposure to the troubled drugmaker after concerns on its leverage. Read more here.

Haier Group still looking to buy Shanghai RAAS stake, Grifols says (NASDAQ:GRFS)

From Seeking Alpha Jan 15, 2024

Spanish plasma therapeutics company Grifols confirms that Haier Group is still planning to acquire a 20% stake in Shanghai RAAS Blood Products, despite...

Why Shares of Grifols Were Up Tuesday

From The Motley Fool May 9, 2023

The company gave first-quarter numbers.

Grifols SA (GRFS) was upgraded to a Buy Rating at Kepler Capital

From TipRanks Sep 28, 2022

Kepler Capital analyst Dariusz Ubik upgraded Grifols SA (GRFS – Research Report) to a Buy on September 26 and set a price target of EUR19.40. The company&#821...

ADVERTISEMENT